Skip to content

Exploring the Comparative Effects of General Anesthesia Combined with Intrathecal Morphine-Ropivacaine Mixture in Major Thoracoabdominal Surgeries and Determining the Optimal Dose of Ropivacaine

Exploring the Comparative Effects of General Anesthesia Combined with Intrathecal Morphine-Ropivacaine Mixture in Major Thoracoabdominal Surgeries and Determining the Optimal Dose of Ropivacaine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105411
Enrollment
Unknown
Registered
2025-07-03
Start date
2025-07-04
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Intrathecal morphine+ropivacaine 6mg group:N/A
Intrathecal morphine group (Group A):N/A
Intrathecal morphine+ropivacaine 4mg group:N/A
Control group (conventional intravenous analgesia group):N/A
Intrathecal morphine+ropivacaine 8mg group:N/A

Sponsors

The Fourth Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Electively perform major chest and abdominal surgery under anesthesia and sign an informed consent form; 2.Age 18-75 years old, American anesthesiologist classification I-II; 3.Those who have not taken analgesics, sedatives or are allergic to them within 72 hours before surgery; 4.The anesthesia time is 2-5 hours; 5.Willing to cooperate with research and postoperative follow-up;

Exclusion criteria

Exclusion criteria: 1.Unable to communicate and cooperate before surgery, resulting in coma, severe dementia, severe mental disorders, etc; 2.Patients with obvious liver, liver and kidney dysfunction and intolerance to surgery; 3.Patients with poor compliance, coagulation dysfunction, spinal deformities, infection at the puncture site, and difficulty cooperating with the puncture operation to complete treatment; 4.Unexpected drug allergy during surgery, switch to open surgery; 5.Unable to follow up within three days after surgery;

Design outcomes

Primary

MeasureTime frame
Observation of intraoperative remifentanil dosage and postoperative 72 hour VAS score;

Secondary

MeasureTime frame
Occurrence of toxic and anesthetic drug-related adverse reactions (postoperative dizziness, respiratory depression, nausea and vomiting, urine retention, catheter-related bladder discomfort (CRBD), pruritus, hypotension, etc.);

Countries

China

Contacts

Public ContactXuesong Ma

The Fourth Affiliated Hospital of Harbin Medical University

mxs13613630888@163.com+86 13613630888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026